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Background/aim: IL-23R gene polymorphisms and the association of these polymorphisms with serum IL-23 levels were investigated in
patients with psoriasis in the current study.
Materials and methods: Sixty-seven patients with psoriasis who were admitted to our dermatology outpatient clinic and 67 healthy
controls were included in the study. Polymorphisms of the IL-23R gene were determined by KASP-PCR method, and serum IL-23 levels
were determined by ELISA method.
Results: The distribution of IL-23R gene polymorphisms rs2201841, rs11209026, rs7530511, rs1343152, and rs11465804 was not
significantly different in the patient and control groups. The AA genotype of the rs2201841 locus in males and the GA genotype in
females, as well as the AA genotype of the rs1343152 locus in males and the CA genotype in females, were statistically significant in
patients with psoriasis. The mean serum IL-23 level was significantly lower in the patient group (42.62 ± 5.96) compared to the control
groups (75.76 ± 13.24).
Conclusion: IL-23R gene polymorphisms including rs2201841, rs11209026, rs7530511, rs11465804, and rs1343152 were not found to be
significantly related to psoriasis. Different genetic polymorphisms may play a role in the development of psoriasis in female and male
populations. Ethnic differences between different populations may have led to differences in the distribution of polymorphisms in the
current study with compared to other published studies. Additionally, many different genes, polymorphisms, and environmental factors
that have an effect on the development of psoriasis may affect the disease process.
Key words: Psoriasis, serum IL-23 levels, IL-23R gene polymorphisms

1. Introduction
Psoriasis is a chronic inflammatory skin disease
characterized by papules and/or plaques that are often
covered with silvery-whitish scales [1]. The presence
of a family history of psoriasis in about 30% of patients,
simultaneous presence of psoriasis in monozygotic twins,
and association of early-onset psoriasis with many major
tissue antigen alleles, especially human leukocyte antigen
(HLA) Cw6, are some of the factors that suggest a role for
genetic factors in the occurrence of the disease [2,3].
Although the pathogenesis of psoriasis is not
known exactly, dysregulation in T cells is thought to
induce keratinocyte proliferation. Studies have shown a
prominent role of the helper T-cell (Th) 17/interleukin
(IL)-23 pathway in the pathogenesis of psoriasis [4,5].

IL-23 is the key cytokine that directs naive CD4+ T cells
to differentiate into Th17 cells by upregulating the IL23 receptor (IL-23R) on naive T cells, resulting in the
secretion of cytokines [4,5].
Previous studies have shown a significant relationship
between psoriasis and some polymorphisms in the IL-23R
gene [6,7]. The IL-23R gene consists of 11 exons and 10
introns; it is localized in chromosome 1p31.3 and is 2912
bp long (Figure). The rs2201841, rs11209026, rs11465804,
rs7530511, and rs1343152 polymorphisms are located in
the 7th intron, 9th exon, 8th intron, 7th exon, and 8th
intron, respectively.
Our study is the first to investigate the relationship
between IL-23R gene polymorphisms and psoriasis in
Turkey. Additionally, our study is the first in the literature
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Figure. Location of IL-23R gene in chromosome 1p31.3.

to investigate the relationship between polymorphisms
rs11465804 and rs1343152 and psoriasis, and also the first
to investigate the relationship between serum IL-23 levels
and rs1343152 rs11209026, rs7530511, and rs11465804
polymorphisms in patients with psoriasis.
The aim of this study was to investigate IL-23R gene
polymorphisms (rs2201841, rs11209026, rs7530511,
rs11465804, rs1343152) and the relationship of these
polymorphisms with serum IL-23 levels and clinical
features of Turkish patients with psoriasis (age at onset,
duration and severity of disease, family history, and nail
and joint involvement).
2. Materials and methods
2.1. Study subjects
The study was initiated after approval from the Süleyman
Demirel University Medical Faculty Clinical Research and
Ethics Committee (decision date 27.12.17 and number
187). An informed consent form was signed by all subjects
of both the patient and control groups. The study included
67 patients aged ≥18 years who were admitted to the
dermatology clinic between December 2017 and August
2018 and 67 healthy controls aged ≥18. Patients with a
clinical and/or histopathological diagnosis of psoriasis,
who did not undergo any systemic treatment in the last 3
months or topical treatment for the last 1 month, and who
did not have any inflammatory disease other than psoriasis
were included in this study. Individuals who did not have
any known disease and did not use any medication were
included in the control group. Cigarette and alcohol users,
breastfeeding and pregnant women, and individuals who
were unwilling to participate were excluded from the study.
2.2. Sample collection and preparation
Peripheral venous blood samples from the patient and
control groups were collected into two blood collection
tubes (EDTA-containing and gel-included biochemistry
tubes) after a fasting period of at least 8 h.
Gel-included biochemistry tubes were centrifuged at
3000 rpm for 10 min and the serum was collected from
these samples. The serum samples were stored at –80 °C
until the determination of serum IL-23 levels by an ELISA
kit in the Medical Biochemistry Laboratory.
Genomic DNA was isolated from whole blood
samples using a commercially available DNA extraction
kit (RTA, DNA and RNA Isolation Kit) according to the

manufacturer’s instructions. Isolated genomic DNA was
analyzed by 0.8% agarose gel electrophoresis to evaluate
the DNA quality; DNA quantity was assessed using
a NanoDrop Spectrophotometer (Thermo Scientific,
Waltham, MA, USA). The DNA samples were stored
at –80 °C until the determination of IL-23R gene single
nucleotide polymorphisms (rs2201841, rs11209026,
rs7530511, rs11465804, rs1343152) by polymerase chain
reaction (PCR) in the Medical Genetics Laboratory.
2.3. Measurement of serum IL-23 levels
Quantitative measurement of serum IL-23 levels was
performed using a commercial ELISA kit according
to the manufacturer’s instructions (Shanghai Sunred
Biological Technology Co., Ltd., Shanghai, China). A
calibration curve was generated by measuring the
standard concentrations and the IL-23 concentration in
each sample was determined by interpolation from the
calibration curve. The detection limit of the assay was
0.522 pg/mL.
2.4. DNA genotyping
Analysis of IL-23R gene polymorphisms rs2201841,
rs11209026, rs7530511, rs11465804, and rs1343152 was
performed by competitive allele-specific PCR (KASP)
assay. All the primers were synthesized by LGC Genomics
(Hoddesdon, UK). Primer sequences are given in Table
1. Reactions were performed according to the following
standard KASP PCR program: activation at 94 °C for 15 min,
then 10 touchdown cycles of 94 °C for 20 s (denaturing),
61–55 °C for 60 s (annealing and elongation), and 23 °C
for 30 s (plate reading), followed by 26 cycles of 94 °C for
20 s, 55 °C for 60 s, and 23 °C for 30 s. Fluorescence was
tracked in real time with plates read at the end of every
amplification cycle. Results were visualized with SNP
Viewer software (version 1.99, Hoddesdon, UK).
2.5. Statistical analysis
Genotype distribution within the groups of patients and
controls were compared with values predicted by Hardy–
Weinberg equilibrium (HWE) using the chi-square test.
HWE was calculated with an online program (http://www.
oege.org/software/hwe-mr-calc.shtml). Explanations for
HWE are also given on that website. Continuous variables
were expressed as mean±SD, and the significance level
was defined as P<0.05. Tests for normality were conducted
with Kolmogorov–Smirnov test. The Mann–Whitney
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U test was used for comparing independent groups for
demographic and clinical data. The difference of allelic and
genotypic frequencies between patient and control groups
was estimated by Pearson’s chi-square test and Fisher’s
exact test. SPSS 18.0 (SPSS Inc., Chicago, IL, USA) was
used to carry out all statistical analyses.
3. Results
The patient and control groups had similar age and sex
distributions (Table 2). The serum IL-23 levels were
significantly lower in the patient group (42.62 ± 5.96)
compared to the controls (75.76 ± 13.24) (Table 2). The
clinical and laboratory features of individuals are shown
in Table 2. There were 44 patients (65.7%) with mild
(Psoriasis Area Severity Index (PASI) score of <10), and
23 patients (34.3%) with moderate-severe (PASI ≥10)
psoriasis. Fourteen patients (20.9%) had nail changes
such as subungual hyperkeratosis, onycholysis, pitting,
and oil drop appearance due to psoriasis. One patient had
psoriatic arthritis, and 21 (31.3%) patients had a family
history of psoriasis (Table 2). Serum IL-23 levels were not
significantly correlated with sex, age, duration of disease,

PASI score, nail and joint involvement, or family history in
the patients or the controls.
The distribution of IL-23R gene polymorphisms
rs2201841, rs11209026, rs7530511, rs1343152, and
rs11465804 was not significantly different in the patient
and control groups (Table 3). Polymorphisms rs2201841
and rs1343152 in 14 patients (7 patients, 7 controls), and
polymorphisms rs11209026, rs7530511, and rs11465804
in thirteen patients (7 patients, 6 controls) could not be
studied due to technical reasons.
The rs2201841 AA genotype was found to be statistically
significantly higher in males while the GA genotype was
statistically significantly higher in female patients with
psoriasis (P = 0.021). No such difference in genotype was
detected in the control group. The rs1343152 variant AA
genotype was found to be statistically significant in males
and the CA genotype in female patients with psoriasis
(P = 0.027); again, no such difference in genotype was
detected in the control group. There was no significant
relationship between genotypes of rs11209026, rs7530511,
and rs11465804 variants and sex in patients with psoriasis
(Table 4).

Table 1. Polymerase chain reaction primers of selected single nucleotide polymorphisms (SNPs) with FAM and HEX fluorescent dyes.
Allele ID
rs2201841

Primer allele
Primer allele
Allele Allele
(FAM)
(HEX)
(FAM) (HEX)
GTAATAGGAAACTAATATAGAAGATGATGACT AATAGGAAACTAATATAGAAGATGATGACC A
G

rs11209026 TTGATTGGGATATTTAACAGATCATTCCA

GGGATATTTAACAGATCATTCCG

A

G

rs7530511

ACTGGCAGCCTTGGAGTTCACT

C

T

rs11465804 AGTATGATGGGTTAAAATGGGCAATTC

CAGTATGATGGGTTAAAATGGGCAATTA

G

T

rs1343152

CTGATAAGAGGCAGAGTTTAATTCAC

A

C

GGCAGCCTTGGAGTTCACC
GATAAGAGGCAGAGTTTAATTCAA

Table 2. Descriptive and comparison statistics of the demographic and clinical features of
patients and controls
PASI: Psoriasis area severity index, SD: standard deviation, n: number.
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Patients (n = 67) Controls (n = 67)

P

Male/female, n (%)

37/30 (55.2%)

31/36 (46.3%)

0.149

Age, years, mean ± SD

40.55 ± 14.83

36.00 ± 13.07

0.062

Initial age of disease, mean ± SD

31.72 ± 1.94

-

Duration of the disease, years, mean ± SD
PASI, mean ± SD
PASI<10, n (%)
PASI ≥10, n (%)
Serum levels of IL-23, mean ± SD

8.90 ± 0.93
10.49 ± 1.34
44 (65.7)
23 (34.3)
42.62 ± 5.96

-

Family history, n (%)

21 (31.3)

Nail involvement, n (%)

14 (20.8)

Psoriatic arthritis, n (%)

1 (1.4)

75.76 ± 13.24

0.024
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Table 3. Genotype distributions of rs2201841, rs11209026,
rs7530511, rs11465804, and rs1343152.
HWE: Hardy–Weinberg equilibrium, n: number.
Genotypes

Patients, n (%)

Controls, n (%)

AA

16 (26.7%)

17 (28.4%)

GA

29 (48.3%)

32 (53.3%)

GG

15 (25%)

11 (18.3%)

HWE

0.797

0.548

GG

58 (96.7%)

57 (93.4%)

GA

2 (3.3%)

4 (6.6%)

AA

0

0

HWE

0.895

0.791

CC

49 (81.7%)

50 (82%)

TC

10 (16.7%)

11 (18%)

TT

1 (1.6%)

0

HWE

0.566

0.438

TT

55 (91.7%)

58 (95.1%)

TG

5 (8.3%)

3 (4.9%)

GG

0

0

HWE

0.736

0.843

AA

13 (21.7%)

15 (25%)

CA

30 (50%)

32 (53.3%)

CC

17 (28.3%)

13 (21.7%)

HWE

0.972

0.599

P

rs2201841
0.673
0.605

rs11209026
0.680
0.684

rs7530511
0.592
0.830

rs11465804
0.491
0.498

rs1343152
0.690
0.519

Serum IL-23 levels were higher in patients with the
rs2201841 variant GA genotype than those with the GA
genotype in the control group but this relationship was
not statistically significant. The serum IL-23 level of one
patient with TT genotype in the rs7530511 variant was
found to be lower than the mean serum IL-23 levels of other
patients with CC and TC genotypes, but this difference
was not statistically significant. There was no statistically
significant relationship between serum IL-23 levels and
rs11209026, rs1343152, and rs11465804 genotype variants
in the patient and control groups (Table 5). Also, there
was no statistically significant relationship between age or
PASI and rs2201841, rs11209026, rs7530511, rs11465804,
and rs1343152 genotype variants (Table 5 and Table 6,
respectively).

The distribution of alleles in the rs2201841, rs11209026,
rs7530511, rs11465804, and rs1343152 polymorphisms
of the IL-23R gene were not significantly different in the
patient and control groups (Table 7). Moreover, IL-23R
gene polymorphisms were not significantly correlated
with clinical features of the patients in this study.
4. Discussion
Once the importance of the Th17/IL-23 pathway in
the pathogenesis of psoriasis was appreciated, many
studies were carried out on polymorphisms of cytokines
and receptor gene associated with this pathway [8].
Serum IL-23 levels were found to be significantly lower
in patients than in controls in the current study. No
significant difference was found between the patient and
control groups in IL-23R gene polymorphisms including
rs2201841, rs11209026, rs7530511, rs11465804, and
rs1343152. Additionally, no significant association was
found between these polymorphisms and serum IL-23
levels.
Studies in which IL-23 levels were significantly
elevated in the serum and skin of patients with psoriasis
have suggested a role of IL-23 in disease pathogenesis [9–
11]. Bai et al. found no significant difference in serum IL23 levels between patients with psoriasis and the control
group in their metaanalysis [12]. However, Michalak et al.
found lower serum IL-23 levels in patients with psoriasis
compared to the control group, but this difference was not
statistically significant [13].
Corroborating the study by Michalak et al., serum IL23 levels were significantly lower in psoriasis patients than
the control group (P = 0.024) in the current study. Serum
IL-23 levels were negatively correlated with the duration of
disease but this was not statistically significant. Alobaidi et
al., who reported a significant negative correlation between
serum IL-23 levels and disease duration, found increased
IL-23 levels in early psoriasis lesions and suggested that
IL-23 was an early mediator that could be implicated in the
formation of psoriatic lesions [11]. Since serum IL-23 levels
were significantly lower in patients with psoriasis and a
negative correlation (albeit statistically not significant) was
detected between serum IL-23 levels and disease duration,
it suggests that IL-23 was responsible for the initiation of
lesions as a primary triggering mediator and that IL-23
was replaced by other cytokines in the later stages of the
disease [11]. In addition, antiinflammatory mechanisms
occurring during the regression period of psoriatic lesions
may also cause a decrease in serum IL-23 levels. It has been
shown that serum IL-23 levels are higher in skin lesions of
psoriatic patients, suggesting the migration of IL-23 to the
skin from the bloodstream, which may lead to a decrease
in serum levels of IL-23 [14,15].
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Table 4. Relationship between genotypes and sex.
n: Number.
Alleles

Groups
Patients (n = 60)

rs2201841

Genotypes Female, n (%)

Male, n (%) P

AA

3 (18.8)

13 (81.3)

GA

18 (62.1)

11 (37.9)

GG

7 (46.7)

8 (53.3)

AA

8 (47.1)

9 (52.9)

Controls (n = 60) GA

Patients (n = 60)
rs11209026

20 (62.5)

12 (37.5)

GG

6 (54.5)

5 (45.5)

AA

-

-

GA

-

2 (100.0)

GG

28 (48.3)

30 (51.7)

AA

-

-

3 (75.0)

1 (25.0)

GG

31 (54.4)

26 (45.6)

CC

23 (46.9)

26 (53.1)

TC

5 (50.0)

5 (50.0)

TT

-

1 (100.0)

CC

26 (52.0)

24 (48.0)

8 (72.7)

3 (27.3)

TT

-

-

TT

26 (47.3)

29 (52.7)

TG

2 (40.0)

3 (60.0)

GG

-

-

TT

32 (55.2)

26 (44.8)

Controls (n = 61) GA

Patients (n = 60)
rs7530511

Controls (n = 61) TC

Patients (n = 60)
rs11465804

Controls (n = 61) TG

Patients (n = 60)
rs1343152

2 (66.7)

1 (33.3)

GG

-

-

AA

2 (15.4)

11 (84.6)

CA

18 (60.0)

12 (40.0)

CC

8 (47.1)

9 (52.9)

AA

7 (46.7)

8 (53.3)

19 (59.4)

13 (40.6)

8 (61.5)

5 (38.5)

Controls (n = 60) CA
CC

There are many studies evaluating the association
between psoriasis and IL-23R rs2201841 polymorphism.
In a metaanalysis, the rs2201841 (A>G) G allele and GG
genotype were found to be associated with psoriasis [16].
Indhumati et al. reported that the CT and CC genotypes
were significantly higher in the psoriasis group at the
rs2201841 (T>C) locus [7]. In another study, occurrence
of the homozygous minor allele (CC) at the locus of
rs2201841 (T>C) was significantly higher in patients
with psoriasis than in controls and the risk of disease
development in CC genotype carriers was reported to

1390

0.021

0.576

0.178

0.442

0.631

0.210

0.755

0.696

0.027

0.660

increase by 2.4-fold [17]. In some studies, no significant
difference was found between the patient and control
groups when AA, GA, and GG genotypes were examined
at the rs2201841 locus [18,19]. In the current study, the
distribution of AA, GA, and GG genotypes and the
distributions of alleles between the patient and control
groups were not found to be significant at the rs2201841
locus. Since the polymorphisms at the rs2201841 locus are
intronic SNPs, it is possible that the polymorphism may
not directly affect receptor function. Alternately, different
polymorphisms such as CC or CT at the rs2201841 locus

FİLİZ et al. / Turk J Med Sci
Table 5. Relationship between genotypes and age and IL-23 levels.
SD: Standard deviation, n: number.
Alleles

Groups

Genotypes n

Age, mean ± SD

P

IL-23 levels, mean ± SD P

RS2201841

Patients

AA

16

40.19 ± 13.78

0.948

31.49 ± 35.44

GA

29

40.66 ± 16.39

GG

15

41.93 ± 15.45

AA

17

27.41 ± 8.73

GA

32

29.41 ± 8.97

75.94 ± 120.47

GG

11

30.18 ± 7.49

81.42 ± 106.85

GG

58

40.38±15.24

GA

2

54.50±10.61

GG

57

28.39 ± 8.42

GA

4

35.00±10.13

CC

49

41.18 ± 15.40

TC

10

39.70 ± 16.05

35.66 ± 42.32

TT

1

36.00

19.28

CC

50

28.82 ± 8.49

TC

11

28.82 ± 9.52

TT

55

40.29 ± 15.61

TG

5

47.00 ± 9.67

TT

58

28.62 ± 8.53

TG

3

32.67 ± 11.02

AA

13

39.69 ± 15.13

CA

30

39.93 ± 15.66

50.27 ± 56.72

CC

17

43.35 ± 15.26

32.91 ± 43.96

AA

15

27.20 ± 8.67

CA

32

28.66 ± 8.74

76.55 ± 120.24

CC

13

31.85 ± 7.97

73.05 ± 99.79

Controls

rs11209026

Patients
Controls

rs7530511

Patients

Controls
rs11465804

Patients
Controls

rs1343152

Patients

Controls

may be associated with psoriasis [7,17]. Ethnic differences
may also be responsible for the lack of association of
disease with this polymorphism in our study since SNPs
may vary in each population.
Another IL-23R gene polymorphism that may be
associated with psoriasis is rs11209026. The GG genotype
at the rs11209026 locus was reported to increase the risk
of psoriasis [20]. The IL-23R gene rs11209026 G minor
allele frequency was reported to be significantly higher in
psoriatic patients [21]. Boyko et al. found no significant
difference in allelic frequencies between the patient and
control groups at the rs11209026 locus and a minor
allele was reported to have a protective effect against the
disease [22]. rs11209026 polymorphism was reported to
be associated with psoriasis in Europeans, although this
polymorphism was not associated with psoriasis in the
Asians [23,24]. The rs11209026 G allele was reported to

0.184

53.57 ± 56.92
28.67 ± 43.10
0.657

0.201

72.25 ± 96.44

41.11 ± 49.34

0.978

0.772

51.55 ± 69.2
0.138

79.09 ± 112.16

0.407

31.81 ± 15.40
0.916

0.999

43.10 ± 51.40

76.72 ± 113.75

0.826

0.912

72.66 ± 89.10
0.351

41.35 ± 50.15

0.956

42.65 ± 44.83
0.431

78.41 ± 111.29

0.450

29.17 ± 17.72
0.733

0.348

32.31 ± 35.36

77.00 ± 102.00

0.391

0.955

be a risk factor for psoriasis in some populations [21,23].
A difference in allele frequency of the rs11209026 A allele
led us to evaluate this as a risky allele for psoriasis in the
current study. The distribution of genotypes and alleles at
the rs11209026 locus (GG, GA) was also not significant,
and the AA genotype was not found in the patient or the
control group. Since the rs11209026 AA polymorphism has
not been studied in our country, we were unable to compare
our results with published data from the same population.
Polymorphisms may vary depending on diseases and
races. Thus, while the association of polymorphisms with a
disease is not significant in one race, it may be a risk factor
for the same disease in a different race.
Boyko et al. reported that the C allele in the IL-23R
gene rs7530511 locus was evaluated as risky for psoriasis,
while the TT, CT, and CC genotypes were not significantly
different between the patient and control groups [22]. In
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Table 6. Relationship between genotypes and PASI.
PASI: Psoriasis Area Severity Index.
Alleles
rs2201841

rs11209026

rs7530511

rs11465804

rs1343152

Genotypes

PASI <10, n (%)

PASI ≥10 n (%) P

AA

11 (68.8)

5 (31.3)

GA

19 (65.5)

10 (34.5)

GG

10 (66.7)

5 (33.3)

AA

-

-

GA

2 (100.0)

0 (0.0)

GG

38 (65.5)

20 (34.5)

CC

33 (67.3)

16 (32.7)

TC

7 (70.0)

3 (30.0)

TT

-

1 (100.0)

TT

35 (63.6)

20 (36.4)

TG

5 (100.0)

0 (0.0)

GG

-

-

AA

8 (61.5)

5 (38.5)

CA

20 (66.7)

10 (33.3)

CC

12 (70.6)

5 (29.4)

Table 7. Distribution of alleles (rs2201841, rs11209026, rs7530511,
rs11465804, rs1343152) by patient and control groups and test
statistics.
n: Number.
Alleles

Patients, n (%)

Controls, n (%) P

Major allele (A)

61 (48.03)

66 (52.21)

Minor allele (G)

59 (51.97)

54 (47.79)

Major allele (G)

118 (50)

118 (50)

Minor allele (A)

2 (33.33)

4 (66.67)

Major allele (C)

108 (49.2)

111 (50.68)

Minor allele (T)

12 (52.17)

11 (47.83)

Major allele (T)

115 (48.52)

122 (51.48)

Minor allele (G)

5 (62.50)

3 (37.50)

Major allele (A)

56 (47.46)

62 (52.54)

Minor allele (C)

64 (52.46)

58 (47.54)

rs2201841
0.518

rs11209026
0.420

rs7530511
0.794

rs11465804
0.437

rs1343152
0.439

a metaanalysis, the rs7530511 T allele was associated with
psoriasis and PsA, and the rs7530511 locus was shown to

1392

0.976

0.309

0.357

0.099

0.873

have protective effects on psoriasis [16]. In the current
study, the T allele was considered to be risky for psoriasis
because the CC genotype was found to be higher in both
patient and control groups when compared to other
genotypes (TC, TT). No significant difference was found
between the CC, TC, and TT genotypes and alleles at the
rs7530511 locus between the patients and controls. The
TT genotype was found in one patient whose serum IL23 level was lower than those of patients with CC and TC
genotypes. This result suggests that the TT genotype may
be associated with serum IL-23 levels, but there is a need
for more patient and control group studies to clarify this
issue.
The CA and CC genotypes of the IL-23R gene at the
rs1343152 locus were reported to be higher in psoriasis
patients than in controls; however, the distribution of
these genotypes was not significantly different between the
patient and control groups [25]. In our study, no significant
difference was found between the patient and control
groups in the distribution of genotypes of AA, CA, and
CC at the rs1343152 locus and TT, TG, and GG genotypes
at the rs11465804 locus. The distribution of alleles at the
rs1343152 and rs11465804 loci was not significant.
In the current study, the rs2201841 AA genotype was
found to be statistically significant in males with psoriasis
while the GA genotype was found to be statistically
significant in women with psoriasis (P = 0.021). Similarly,
the rs1343152 AA genotype was found to be statistically
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significant in men while the CA genotype was significant
in women in the psoriasis group (P = 0.027). This suggests
that different genetic polymorphisms may play a role in the
development of psoriasis in female and male populations.
Women with the rs2201841 GA and rs1343152 CA
genotypes and men with rs1343152 AA and rs1343152 AA
genotypes may be susceptible to psoriasis. However, the
sex-dependent associations need to be validated in larger
sample sizes as well as in other populations.
To our knowledge, there is only one other study in the
published literature investigating serum IL-23 levels in
psoriasis patients with the rs2201841 (T>C) polymorphism
in the IL-23R gene [7]. In the current study, serum IL-23
levels were found to be significantly higher in patients
with the CC genotype compared to those with CT and
TT genotypes at the rs2201841 locus in the patient group.
Corroborating the current study, serum IL-23 levels were
also found to be higher in patients with the GA genotype
at the rs2201841 locus in the patient group compared to
those with the GA genotype in the control group, but this
difference was not statistically significant. The relationship
between serum IL-23 level and rs2201841 GA genotype
can be evaluated more clearly in further studies involving
more patients.
Our study has some limitations. A relatively small
number of patients and no evaluation of the association
of IL-23R gene polymorphisms (rs2201841, rs11209026,
rs7530511, rs11465804, rs1343152) with other cytokines

(IL-17 and IL-22) were the main limitations of our study.
On the other hand, our study was the first investigating
the relationship between rs11465804 and rs1343152
polymorphisms and psoriasis and also examining the
relationship between serum IL-23 levels and rs1343152
rs11209026, rs7530511, and rs11465804 polymorphisms
in patients with psoriasis in the literature. This study is
also the first investigating the relationship between IL-23R
gene polymorphisms and psoriasis in Turkey.
In conclusion, different results were obtained when
our genotyping data and biochemical parameters
were compared with the data currently available in the
literature. This result may be due to the fact that studies
included varying numbers of patients with different ethnic
backgrounds. Moreover, interactions of many different
genes, polymorphisms, and environmental factors
contribute to the development of a disease process. Further
studies are needed to investigate IL-23R polymorphisms
in serum and skin lesions together with IL-17 levels and to
evaluate more candidate IL-23R gene polymorphisms in
larger groups of patients with psoriasis. Studies comparing
serum and lesional (skin) IL-23 levels will reveal changes
in serum IL-23 levels more clearly.
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